Philip R. Olivieri

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Marc Payton, Tammy L. Bush, Grace Chung et al. · Cancer Research · 2010 · 118 citations · Full text

Cell Death, Novel Potent, Cancer Biology +18

Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor

Brian L. Hodous, Stephanie Geuns-Meyer, Paul E. Hughes et al. · Journal of Medicinal Chemistry · 2007 · 91 citations · Full text

Molecular Biology, Pharmacotherapy, Chemical Biology +21

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase

Victor J. Cee, Alan C. Cheng, Karina Romero et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 64 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Tie-2 Kinase +12

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity

Laurie B. Schenkel, Philip R. Olivieri, Alessandro A. Boezio et al. · Journal of Medicinal Chemistry · 2016 · 60 citations · Full text

Pain Medicine, Molecular Pain, Pharmacotherapy +17

Discovery of <i>N</i>-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

Stephanie Geuns-Meyer, Victor J. Cee, Holly L. Deak et al. · Journal of Medicinal Chemistry · 2015 · 44 citations · Full text

Pharmacotherapy, Pharmaceutical Chemistry, Tumor Biology +19